Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers

Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers

Aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds are sodium channel blockers; pharmaceutical compositions that include an effective amount of the aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds and a pharmaceutically acceptable carrier...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Kuo, Howard C. H, Ayer, Michelle B, Chakravarty, Prasun K, Meinke, Peter T, Parsons, William H, Tyagarajan, Sriram
Format: Patent
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Kuo, Howard C. H
Ayer, Michelle B
Chakravarty, Prasun K
Meinke, Peter T
Parsons, William H
Tyagarajan, Sriram
description Aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds are sodium channel blockers; pharmaceutical compositions that include an effective amount of the aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds and a pharmaceutically acceptable carrier, and a method of treatment of acute pain, chronic pain, visceral pain, inflammatory pain, or neuropathic pain, as well as initable bowel syndrome, Cnohns disease, epilepsy, partial and generalized tonic seizures, multiple sclerosis, bipolar depression, and tachy-arrhythmias by the administration of an effective amount of aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds are described.
format Patent
fullrecord <record><control><sourceid>uspatents_EFH</sourceid><recordid>TN_cdi_uspatents_grants_07348348</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>07348348</sourcerecordid><originalsourceid>FETCH-uspatents_grants_073483483</originalsourceid><addsrcrecordid>eNqNijEKAkEMRaexEPUOucCAoKCtiOIBrJXsTnTDxoxMMqCeXhfsbIQH7_H543DalKdEYe0jfgqsNubs1SmBd4yvLJxYKSbOSoCaID9-VgPLiesN2g5VSaCR3PZUbBpGFxSj2deTAPvdcXuI1e7opG7na8FB89ViuR744_IGVeE-PQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers</title><source>USPTO Issued Patents</source><creator>Kuo, Howard C. H ; Ayer, Michelle B ; Chakravarty, Prasun K ; Meinke, Peter T ; Parsons, William H ; Tyagarajan, Sriram</creator><creatorcontrib>Kuo, Howard C. H ; Ayer, Michelle B ; Chakravarty, Prasun K ; Meinke, Peter T ; Parsons, William H ; Tyagarajan, Sriram ; Merck &amp; Co. Inc</creatorcontrib><description>Aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds are sodium channel blockers; pharmaceutical compositions that include an effective amount of the aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds and a pharmaceutically acceptable carrier, and a method of treatment of acute pain, chronic pain, visceral pain, inflammatory pain, or neuropathic pain, as well as initable bowel syndrome, Cnohns disease, epilepsy, partial and generalized tonic seizures, multiple sclerosis, bipolar depression, and tachy-arrhythmias by the administration of an effective amount of aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds are described.</description><language>eng</language><creationdate>2008</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7348348$$EPDF$$P50$$Guspatents$$Hfree_for_read</linktopdf><link.rule.ids>230,308,780,802,885,64039</link.rule.ids><linktorsrc>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7348348$$EView_record_in_USPTO$$FView_record_in_$$GUSPTO$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Kuo, Howard C. H</creatorcontrib><creatorcontrib>Ayer, Michelle B</creatorcontrib><creatorcontrib>Chakravarty, Prasun K</creatorcontrib><creatorcontrib>Meinke, Peter T</creatorcontrib><creatorcontrib>Parsons, William H</creatorcontrib><creatorcontrib>Tyagarajan, Sriram</creatorcontrib><creatorcontrib>Merck &amp; Co. Inc</creatorcontrib><title>Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers</title><description>Aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds are sodium channel blockers; pharmaceutical compositions that include an effective amount of the aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds and a pharmaceutically acceptable carrier, and a method of treatment of acute pain, chronic pain, visceral pain, inflammatory pain, or neuropathic pain, as well as initable bowel syndrome, Cnohns disease, epilepsy, partial and generalized tonic seizures, multiple sclerosis, bipolar depression, and tachy-arrhythmias by the administration of an effective amount of aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds are described.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2008</creationdate><recordtype>patent</recordtype><sourceid>EFH</sourceid><recordid>eNqNijEKAkEMRaexEPUOucCAoKCtiOIBrJXsTnTDxoxMMqCeXhfsbIQH7_H543DalKdEYe0jfgqsNubs1SmBd4yvLJxYKSbOSoCaID9-VgPLiesN2g5VSaCR3PZUbBpGFxSj2deTAPvdcXuI1e7opG7na8FB89ViuR744_IGVeE-PQ</recordid><startdate>20080325</startdate><enddate>20080325</enddate><creator>Kuo, Howard C. H</creator><creator>Ayer, Michelle B</creator><creator>Chakravarty, Prasun K</creator><creator>Meinke, Peter T</creator><creator>Parsons, William H</creator><creator>Tyagarajan, Sriram</creator><scope>EFH</scope></search><sort><creationdate>20080325</creationdate><title>Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers</title><author>Kuo, Howard C. H ; Ayer, Michelle B ; Chakravarty, Prasun K ; Meinke, Peter T ; Parsons, William H ; Tyagarajan, Sriram</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-uspatents_grants_073483483</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2008</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Kuo, Howard C. H</creatorcontrib><creatorcontrib>Ayer, Michelle B</creatorcontrib><creatorcontrib>Chakravarty, Prasun K</creatorcontrib><creatorcontrib>Meinke, Peter T</creatorcontrib><creatorcontrib>Parsons, William H</creatorcontrib><creatorcontrib>Tyagarajan, Sriram</creatorcontrib><creatorcontrib>Merck &amp; Co. Inc</creatorcontrib><collection>USPTO Issued Patents</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Kuo, Howard C. H</au><au>Ayer, Michelle B</au><au>Chakravarty, Prasun K</au><au>Meinke, Peter T</au><au>Parsons, William H</au><au>Tyagarajan, Sriram</au><aucorp>Merck &amp; Co. Inc</aucorp><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers</title><date>2008-03-25</date><risdate>2008</risdate><abstract>Aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds are sodium channel blockers; pharmaceutical compositions that include an effective amount of the aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds and a pharmaceutically acceptable carrier, and a method of treatment of acute pain, chronic pain, visceral pain, inflammatory pain, or neuropathic pain, as well as initable bowel syndrome, Cnohns disease, epilepsy, partial and generalized tonic seizures, multiple sclerosis, bipolar depression, and tachy-arrhythmias by the administration of an effective amount of aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds are described.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_uspatents_grants_07348348
source USPTO Issued Patents
title Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T19%3A08%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-uspatents_EFH&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Kuo,%20Howard%20C.%20H&rft.aucorp=Merck%20&%20Co.%20Inc&rft.date=2008-03-25&rft_id=info:doi/&rft_dat=%3Cuspatents_EFH%3E07348348%3C/uspatents_EFH%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true